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Fighting a deadly fungus:
A new strategy to reduce deaths due to Cryptococcus
Cryptococcal meningitis is a leading cause of death among people 
living with HIV.  In sub-Saharan Africa, it is estimated to kill more 
people than tuberculosis.
The infection caused by 
Cryptococcus “is one 
of the most dangerous 
HIV-related issues…
HIV therapy programs 
should not neglect to 
address this still lethal 
disease.”
Vincenzo Esposito and Antonio 
Chirianni, HIV Therapy 2010
Why is Cryptococcus a major public health issue?
 • It is a leading cause of death among people living with HIV.
 • Cryptococcus is the most common cause of meningitis in Africa. 
Meningitis develops after the dormant fungus has been reactivated. For 
people living with HIV, it can be triggered when their CD4+ count drops.
 • Cryptococcal meningitis mortality is high (50–70%).
 • In developing countries, medication to treat cryptococcal meningitis is 
often unavailable or too expensive. 
 • Management of cryptococcal meningitis is intensive, requiring frequent 













Estimated causes of death in sub-Saharan Africa, 
excluding HIV, 2009
Adapted from Park, et al., AIDS 2009
What is Cryptococcus?
Cryptococcus is a fungus that is found in the soil and produces spores 
that can be inhaled. People can get Cryptococcus early in life but never 
know it. If a person’s immune system is weakened (for example, by HIV), 
Cryptococcus can cause a life-threatening infection called cryptococcal 
meningitis.
May 2011 
By 2015, equip one-half of all HIV clinics in Africa and 
Asia to perform Cryptococcus testing and treatment. 
This could save 50,000–100,000 lives each year.
“The magnitude of the 
benefit of …screening 
[for Cryptococcus] is 
overwhelming.”
David Meya et al., Clinical 
Infectious Diseases  2010
Because it is not possible to prevent the initial infection, it is best to screen 
people who have been exposed to Cryptococcus to prevent meningitis 
from developing. A novel dipstick screening test (currently pending FDA 
approval) has just been developed that is
New solutions for treating Cryptococcus
Cryptococcus: A call to action
Affordable: The medication that can be used 
before meningitis develops (oral fluconazole), 
is free or inexpensive ($1–$2 per month)
Cost-effective ($180/life year gained), 
similar to other more widely used preventive 
measures, such as co-trimoxazole prophylaxis 
or tuberculosis preventive therapy
Lifesaving: Studies where people were 
treated before developing meningitis have 
demonstrated better outcomes
Simple:  It‘s easy to learn how to perform the test and read the 
results
Available: It’s a test that can be performed in the clinic, so 
people who live in remote rural areas (where there are no 
laboratories nearby) can use it, too 
Effective: The test is highly sensitive and highly 
accurate (>95%)
Affordable: It costs less than $2 per test
Quick: Results are available in 10 minutes
If screening detects the 
presence of Cryptococcus, 
beginning treatment at this 
point—before meningitis 
develops—is
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